Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clomipramine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Clomipramine is a tricyclic antidepressant (TCA) primarily indicated for the treatment of obsessive-compulsive disorder (OCD) in adults and children aged 10 years and older. It acts mainly as a potent serotonin reuptake inhibitor, increasing serotonin levels in the brain to help maintain mental balance. Clomipramine also inhibits norepinephrine reuptake through its active metabolite, desmethylclomipramine, and exhibits antagonistic activity at several serotonin receptor subtypes. Additional pharmacological effects include alpha-1 adrenergic receptor blockade and sodium channel inhibition, which may contribute to its analgesic properties in neuropathic pain. The drug is available as oral capsules in various strengths[1][4][5][7].
- Brand names
- Anafranil
- Other names
- clomipramine hydrochloride
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)
Beyond the preview
Go deeper on clomipramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clomipramine.